These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25170660)

  • 1. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
    Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Int J Pharm; 2012 Oct; 436(1-2):318-23. PubMed ID: 22772485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
    Wasan EK; Gershkovich P; Zhao J; Zhu X; Werbovetz K; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e913. PubMed ID: 21151883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
    Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
    Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
    Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
    J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
    Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
    J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1277-83. PubMed ID: 22989082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
    Mohamed HA; Radwan RR; Raafat AI; Ali AE
    Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model.
    Sivak O; Gershkovich P; Lin M; Wasan EK; Zhao J; Owen D; Clement JG; Wasan KM
    Lipids Health Dis; 2011 Aug; 10():135. PubMed ID: 21824435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
    Wasan KM; Conklin JS
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
    Kretschmar M; Nichterlein T; Hannak D; Hof H
    Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
    Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
    J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a poly-aggregated formulation of amphotericin B in treating systemic sporotrichosis caused by Sporothrix brasiliensis.
    Ishida K; Castro RA; Torrado JJ; Serrano DR; Borba-Santos LP; Quintella LP; de Souza W; Rozental S; Lopes-Bezerra LM
    Med Mycol; 2018 Apr; 56(3):288-296. PubMed ID: 28575449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
    Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High purity amphotericin B.
    Cleary JD; Chapman SW; Swiatlo E; Kramer R
    J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.